PortalPublikationenPrognostic significance of DNA cytometry for adjuvant therap...

Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer

Standard

Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. / Klein, Fritz; Bahra, Marcus; Schirmeier, Anja; Al-Abadi, Hussein; Pratschke, Johann; Pelzer, Uwe; Oettle, Helmut; Striefler, Jana; Riess, Hanno; Sinn, Marianne.

in: J SURG ONCOL, Jahrgang 112, Nr. 1, 07.2015, S. 66-71.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klein, F, Bahra, M, Schirmeier, A, Al-Abadi, H, Pratschke, J, Pelzer, U, Oettle, H, Striefler, J, Riess, H & Sinn, M 2015, 'Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer', J SURG ONCOL, Jg. 112, Nr. 1, S. 66-71. https://doi.org/10.1002/jso.23951

APA

Klein, F., Bahra, M., Schirmeier, A., Al-Abadi, H., Pratschke, J., Pelzer, U., Oettle, H., Striefler, J., Riess, H., & Sinn, M. (2015). Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. J SURG ONCOL, 112(1), 66-71. https://doi.org/10.1002/jso.23951

Vancouver

Klein F, Bahra M, Schirmeier A, Al-Abadi H, Pratschke J, Pelzer U et al. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. J SURG ONCOL. 2015 Jul;112(1):66-71. https://doi.org/10.1002/jso.23951

Bibtex

@article{7a98ba7684454e19938711e709be2bb0,
title = "Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer",
abstract = "BACKGROUND AND OBJECTIVES: The continuous progress in treatment options for pancreatic adenocarcinoma has lead to a re-evaluation of prognostic markers. In this study the prognostic relevance of DNA Index and classical histopathological parameters with regard to disease-free (DFS) and overall survival (OS) was analyzed within the CONKO-001 patient population.METHODS: One hundred forty three fresh-frozen paraffin-embedded tissue samples of the resected tumor specimen of the CONKO-001 patient population were available for DNA index analysis to evaluate its impact on patient outcome.RESULTS: Median DFS (7.3 vs. 14.3 months; P = 0.004) and median OS (16.6 vs. 29.2 months; P = 0.011) were significantly decreased in patients with a high DNA index (>1.4). Multivariate analysis revealed both DNA index (DFS: P = 0.002; OS: P = 0.019) and tumor grading (DFS: P = 0.004; OS: P = 0.004) as individual prognostic markers for DFS and OS. The following prognostic subgroups were identified: good (low DNA Index + G1/2 tumor grading), intermediate (low DNA Index + G3 tumor grading or high DNA Index + G1/2 tumor grading), poor (high DNA Index + G3 tumor grading).CONCLUSION: The DNA index/tumor grading constellation may serve as a helpful guide for personalized treatment recommendations for adjuvant therapy of patients with pancreatic adenocarcinoma.",
keywords = "Adenocarcinoma/drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Chemotherapy, Adjuvant, DNA, Neoplasm/analysis, Female, Follow-Up Studies, Humans, Image Cytometry/methods, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Pancreatic Neoplasms/drug therapy, Prognosis, Survival Rate, Tissue Array Analysis",
author = "Fritz Klein and Marcus Bahra and Anja Schirmeier and Hussein Al-Abadi and Johann Pratschke and Uwe Pelzer and Helmut Oettle and Jana Striefler and Hanno Riess and Marianne Sinn",
note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",
year = "2015",
month = jul,
doi = "10.1002/jso.23951",
language = "English",
volume = "112",
pages = "66--71",
journal = "J SURG ONCOL",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer

AU - Klein, Fritz

AU - Bahra, Marcus

AU - Schirmeier, Anja

AU - Al-Abadi, Hussein

AU - Pratschke, Johann

AU - Pelzer, Uwe

AU - Oettle, Helmut

AU - Striefler, Jana

AU - Riess, Hanno

AU - Sinn, Marianne

N1 - © 2015 Wiley Periodicals, Inc.

PY - 2015/7

Y1 - 2015/7

N2 - BACKGROUND AND OBJECTIVES: The continuous progress in treatment options for pancreatic adenocarcinoma has lead to a re-evaluation of prognostic markers. In this study the prognostic relevance of DNA Index and classical histopathological parameters with regard to disease-free (DFS) and overall survival (OS) was analyzed within the CONKO-001 patient population.METHODS: One hundred forty three fresh-frozen paraffin-embedded tissue samples of the resected tumor specimen of the CONKO-001 patient population were available for DNA index analysis to evaluate its impact on patient outcome.RESULTS: Median DFS (7.3 vs. 14.3 months; P = 0.004) and median OS (16.6 vs. 29.2 months; P = 0.011) were significantly decreased in patients with a high DNA index (>1.4). Multivariate analysis revealed both DNA index (DFS: P = 0.002; OS: P = 0.019) and tumor grading (DFS: P = 0.004; OS: P = 0.004) as individual prognostic markers for DFS and OS. The following prognostic subgroups were identified: good (low DNA Index + G1/2 tumor grading), intermediate (low DNA Index + G3 tumor grading or high DNA Index + G1/2 tumor grading), poor (high DNA Index + G3 tumor grading).CONCLUSION: The DNA index/tumor grading constellation may serve as a helpful guide for personalized treatment recommendations for adjuvant therapy of patients with pancreatic adenocarcinoma.

AB - BACKGROUND AND OBJECTIVES: The continuous progress in treatment options for pancreatic adenocarcinoma has lead to a re-evaluation of prognostic markers. In this study the prognostic relevance of DNA Index and classical histopathological parameters with regard to disease-free (DFS) and overall survival (OS) was analyzed within the CONKO-001 patient population.METHODS: One hundred forty three fresh-frozen paraffin-embedded tissue samples of the resected tumor specimen of the CONKO-001 patient population were available for DNA index analysis to evaluate its impact on patient outcome.RESULTS: Median DFS (7.3 vs. 14.3 months; P = 0.004) and median OS (16.6 vs. 29.2 months; P = 0.011) were significantly decreased in patients with a high DNA index (>1.4). Multivariate analysis revealed both DNA index (DFS: P = 0.002; OS: P = 0.019) and tumor grading (DFS: P = 0.004; OS: P = 0.004) as individual prognostic markers for DFS and OS. The following prognostic subgroups were identified: good (low DNA Index + G1/2 tumor grading), intermediate (low DNA Index + G3 tumor grading or high DNA Index + G1/2 tumor grading), poor (high DNA Index + G3 tumor grading).CONCLUSION: The DNA index/tumor grading constellation may serve as a helpful guide for personalized treatment recommendations for adjuvant therapy of patients with pancreatic adenocarcinoma.

KW - Adenocarcinoma/drug therapy

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Biomarkers, Tumor/analysis

KW - Chemotherapy, Adjuvant

KW - DNA, Neoplasm/analysis

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Image Cytometry/methods

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Pancreatic Neoplasms/drug therapy

KW - Prognosis

KW - Survival Rate

KW - Tissue Array Analysis

U2 - 10.1002/jso.23951

DO - 10.1002/jso.23951

M3 - SCORING: Journal article

C2 - 26193339

VL - 112

SP - 66

EP - 71

JO - J SURG ONCOL

JF - J SURG ONCOL

SN - 0022-4790

IS - 1

ER -